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Bone morphogenetic proteins (BMPs) can either promote growth of embryonic muscle by expanding the Pax-3-expressing
muscle precursor population or restrict its development by inducing apoptosis. Follistatin, a proposed BMP antagonist, is
expressed in embryonic muscle. Deficiency in Follistatin results in muscle defects and postnatal asphyxia. Here, we report
that during chick limb development Follistatin enhances BMP-7 action to induce muscle growth but prevents the ability
of BMP-7 to induce apoptosis and muscle loss. Follistatin, unlike another BMP-binding protein, Noggin, promotes Pax-3
expression and transiently delays muscle differentiation and thus exerts proliferative signalling during muscle development.
We provide data which show that Follistatin binds BMP-7 and BMP-2 at low affinities and that the binding is reversible.
These data suggest that Follistatin acts to present BMPs to myogenic cells at a concentration that permits stimulation of
embryonic muscle growth. © 2002 Elsevier Science (USA)
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Growing skeletal muscle requires a pool of dividing
mononucleated muscle precursors since differentiated
muscle cells are mitotically quiescent (Olson, 1992). The
size of the proliferating cell population depends on the rate
of proliferation, the rate of differentiation, and the rate at
which cells are eliminated through cell death. Intercellular
signalling provides essential information about when and
where to proliferate, to differentiate, or to be eliminated
through cell death, which ensures development of correctly
sized and positioned muscle (Amthor et al., 1998).
Muscle development of the limb is an excellent model in
which to study how signalling molecules balance prolifera-
tion, differentiation, and apoptosis. A small number of
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All rights reserved.dividing muscle precursors migrate from the lateral edges of
the somites and invade the limb mesenchyme (Chevallier
et al., 1977; Christ et al., 1974). The embryo uses this
limited population of cells to form all the musculature of
the limb. We have previously shown that dividing muscle
precursors of the developing limb can be marked by the
expression of Pax-3 (Amthor et al., 1998), a gene which
encodes a transcription factor of the Paired-box family
(Strachan and Read, 1994; Tassabehji et al., 1994). Myo-
genic cells differentiate only after having down-regulated
Pax-3 expression, become postmitotic, and express MyoD
(Amthor et al., 1998), a gene which encodes a transcription
factor of the myogenic regulatory family (Emerson, 1993;
Sassoon et al., 1989). We have shown that, in the absence of
proliferation-enhancing signals, myogenic cells automati-
cally and precociously differentiate, which initially en-
larges muscle masses. However, further muscle growth is
arrested because the pool of Pax-3-expressing muscle pre-
cursors is exhausted (Amthor et al., 1998, 1999). Con-
versely, stimulation of Pax-3 expression after exposure of1027. E-mail: kpatel@rvc.ac.uk.Developmental Biology 243, 115–127 (2002)
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developing limb muscle to Sonic Hedgehog is linked to a
transient delay of muscle differentiation, which results in
excessive muscle growth (Amthor et al., 1998; Duprez et
al., 1998).
Growth factors of the bone morphogenetic protein (BMP)
family have been shown to be key signals that regulate
embryonic muscle growth based on their sites of expres-
sion, which are situated adjacent to dividing muscle cells,
and their ability to up-regulate Pax-3 expression (Amthor et
al., 1998; Pourquie et al., 1996). In addition to stimulating
muscle growth, BMPs can restrict muscle growth by induc-
ing apoptosis. These opposing activities are concentration-
dependent because BMP protein applied at low concentra-
tions stimulates Pax-3 expression, whereas BMP applied at
higher concentrations induces apoptosis (Amthor et al.,
1998).
However, the characterisation of secreted factors, includ-
ing Follistatin, Noggin, and Chordin, which modulate the
activity of BMPs in a variety of developmental systems,
challenge the rather simple model of a morphogen gradient
being established simply by diffusion (Fainsod et al., 1997;
Piccolo et al., 1996; Sasai et al., 1995; Wolpert, 1978;
Zimmerman et al., 1996). Previous work has demonstrated
that concentration gradients of BMP and counter gradients
of Noggin specify paraxial, intermediate, and lateral meso-
derm in vertebrates (Neave et al., 1997). Furthermore, even
within the paraxial compartment, Pourquie et al. (1996)
have demonstrated that BMP maintains myogenic cells in
an undifferentiated Pax-3-expressing state in the lateral
somite halves, whereas Noggin induces MyoD expression
and initiates differentiation in cells of the medial part of the
somites (Capdevila and Johnson, 1998; Hirsinger et al.,
1997). A similar organisation is found during limb develop-
ment. Ectodermal, subectodermal, and marginal BMP ex-
pression is countered by Noggin expression in the mesen-
chymal core. Pax-3-expressing cells are located adjacent to
the BMP source, and MyoD-expressing cells are located
closer to the Noggin source (Amthor et al., 1998).
Follistatin is expressed in muscle precursors of somites,
in myotomal, and in limb muscle (Amthor et al., 1996;
Connolly et al., 1995). Genetic deletion of Follistatin in
mice results in generalised growth retardation, decreased
muscle mass, especially of respiratory muscle, and postna-
tal asphyxia (Matzuk et al., 1995). However, the molecular
mechanism which enables Follistatin to support muscle
growth is not known. Follistatin is a secreted glycoprotein
of approximately 32–39 kDa and was originally character-
ised by its ability to antagonise activin-stimulated secretion
of follicle-stimulating hormone (Michel et al., 1993; Patel,
1998). During early Xenopus development, Follistatin, like
Noggin and Chordin, antagonises BMP signalling, which
enables specification of dorsal mesoderm and neuroecto-
derm (Fainsod et al., 1997). Follistatin interacts directly
with BMP but does not prevent the ligand binding to its
receptor (Iemura et al., 1998). However, it has been sug-
gested that conformational changes of BMP caused by
Follistatin binding prevent receptor activation (Iemura et
al., 1998).
In this study, we aimed to determine the role of Follista-
tin during embryonic limb muscle development. We ap-
plied beads soaked in Follistatin protein to developing chick
wing buds and found that Follistatin promotes expression of
the proliferation marker Pax-3 and inhibits the expression
of the differentiation marker MyoD. We compared effects of
Follistatin with BMP and used beads soaked in BMP-7
protein as a representative of this family. Low concentration
BMP-7 stimulates Pax-3 expression, but high concentration
BMP-7 induces apoptosis and loss of muscle. When Follista-
tin was applied together with a high concentration of
BMP-7, it enhanced the effect of BMP-7 to stimulate Pax-3
expression, prevented BMP-7-induced apoptosis, and re-
sulted in excessive muscle growth. We compared the ability
of Follistatin to induce muscle with another BMP-binding
protein, Noggin. In contrast to the muscle-promoting abil-
ity of Follistatin, Noggin inhibits Pax-3 expression, which
results in muscle growth retardation. This shows that
Noggin blocks the muscle growth-stimulation effect of
BMP on muscle. In order to fully understand the nature of
the interaction of Follistatin with BMPs, we studied the
binding kinetics between these proteins using surface plas-
mon resonance. We present data which show that Follista-
tin interacts with BMP-2 and -7 at low affinities. We present
a model to explain the experimental findings and suggest
that Follistatin acts to present BMPs to muscle at concen-
trations which permit stimulation of embryonic muscle
growth.
MATERIALS AND METHODS
Preparation of Chick Embryos
Fertilised chicken eggs were incubated at 38°C, and the embryos
were staged according to Hamburger and Hamilton (1992). Experi-
ments were performed on embryos at stage 17–24, reincubated for
a total of 6 days, sacrificed, and processed for whole-mount in situ
hybridisation or antibody staining.
BMP-7 and Follistatin Bead Preparation
BMP-7 was provided by Creative BioSciences as part of a mate-
rial transfer agreement between KP and Creative BioSciences.
BMP-2 was supplied by Genetics Institute. Follistatin was provided
by National Hormone and Pituitary Program. Proteins were applied
to 80- to 120-m heparin acrylic beads (Sigma, UK). BMP-7 was
used at concentrations stated in the text. Follistatin was used at a
concentration of 1 mg/ml. Proteins were loaded onto beads as
described by Cohn et al. (1995).
Bead Application and Microsurgical Procedures
For bead implantation, the dorsal ectoderm and mesenchyme of
the right wing or somites were punctured with a electrolytically
sharpened tungsten needle, and beads were inserted into the
punctured mesenchyme by using a blunt glass needle.
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Apoptosis Assay
Acridine Orange is a cationic fluorescent dye that accumulates
in condensing chromatin of apoptotic nuclei, which can be visual-
ised as fluorescent spots in the FITC spectrum (Erenpreisa et al.,
1997). Wing buds were dissected free of all unwanted tissue and
then incubated in Acridine Orange (100 ng/ml in PBS) at 37°C for
30 min. Specimens were then washed two times for 5 min in PBS
and then flattened on a microscope slide under a coverslip (Weil et
al., 1997). Samples were analysed and photographed immediately
by using fluorescence illumination and confocal microscopy and
then were fixed in 4% paraformaldehyde for in situ hybridisation.
Whole-Mount in Situ Hybridisation
All chick embryos were washed in PBS and then fixed overnight
in 4% paraformaldehyde at 4°C. Anti-sense RNA probes were
labelled with digoxigenin, and whole-mount in situ-hybridisation
was performed as described by Nieto et al. (1996). The following
probes were used in this study: Bmp-2, PCR cloned fragment
(nucleotides 1–797); Bmp-4, PCR cloned fragment (nucleotides
1–953); Bmp-7, full-length fragment, 1.1 kb (gift from Dr. Anthony
Graham); Follistatin, full-length, 1.1-kb fragment; MyoD, clone
CMD9 full-length, 1.5-kb fragment (gift from Bruce Patterson);
Noggin, full-length clone, approximately 700 bp; and Pax-3, 645-bp
fragment corresponding to nucleotides 468-1113 (gift from Dr.
Martin Goulding). Whole-mount embryos were partially cryosec-
tioned for further histological examination.
Immunohistochemistry on Whole Mounts
Embryos were fixed overnight in 4% paraformaldehyde (PFA),
dehydrated into 100% methanol, incubated for 1 h in 5:1
Methanol/H2O2, washed in PBT (PBS containing 0.5% Triton),
incubated for 1 h in 10% horse serum (in PBT), incubated overnight
with an anti-Desmin monoclonal antibody (DAKO; 1:100, in horse
serum/PBT), washed in PBT, incubated overnight in secondary
antibody (AP-conjugated goat anti-mouse Ig antibody; Sigma;
1:300, in horse serum/PBT), washed in PBT, transferred in AP-
buffer (Nieto et al., 1996), incubated for 5–10 min in colour reagent
(4.5 l NBT and 3.5 l BCIP in 1 ml AP-buffer; Boehringer-
Mannheim), washed in AP-buffer and cleared in dimethylform-
amide, and stored in 4% PFA.
Virus Preparation and Injections
Noggin-RCAS constructs were kindly provided by Dr. Randy
Johnson. Noggin virus was produced according to Capdevila and
Johnson (1998), and viral titres of 108 pfu/ml were obtained. For
injections, 1 l of Fast Green (0.01% stock) was mixed with 9 l of
virus to aid visualisation and was injected at various pulse times by
using a PM1000 cell microinjector (Micro Data Instruments).
Cell Grafting
Noggin expression chick “O” Line fibroblasts were trypsinised
and pelleted in growth medium at 1000g for 5 min. The pellet was
subsequently resuspended in 1 ml of culture medium in a 2-ml
Eppendorf tube. The cells were pelleted at 1000g for 10 min. The
pellet was removed by running a wire loop between the pellet and
the bottom of the tube. The pellet was placed into a sterile plastic
plate and bathed in culture medium and then cut into fragments for
grafting.
BMP–Follistatin Interaction Analysis by Surface
Plasmon Resonance
Binding experiments were performed by using the BIACORE
2000 (Biacore AB). Purified recombinant human Follistatin was
immobilised onto the surface of a CM5 sensor chip (657.3 reso-
nance units) by using amine-coupling chemistry. Purified recom-
binant BMP-2 and BMP-7 were injected over the sensor chip
surfaces at a flow rate of 5 l/min at 25°C. For controls, the BMPs
were run over derivatised sensor chip surfaces which lacked
Follistatin. Hepes-buffered saline (HBS; 10 mM Hepes, 150 mM
NaCl, 3.4 mM EDTA, 0.005% Tween 20, pH 7.4) was used for
sample dilution and as a running buffer. All curves were corrected
by subtraction of the blank run. Biacore evaluation software was
used for the mathematical adaptation of experimental curves.
RESULTS
Expression of Follistatin, BMPs, and Muscle
Markers during Wing Bud Development
Distribution of Follistatin mRNA was analysed in
muscle of HH stage 28–29 chick wings by in situ hybridi-
sation and was compared with the Pax-3-expressing popu-
lation of proliferating muscle precursors, with the MyoD-
expressing population of differentiating myogenic cells, and
with the Desmin-expressing population of terminally dif-
ferentiated muscle cells (Fig. 1).
At HH stage 28, differentiated limb muscle identified by
Desmin expression extended from the shoulder girdle into
the autopod, and proximal muscle had begun to split into
individual blocks (Fig. 1A). Transverse sections of the
zeugopod showed uniform levels of Desmin expression in
the dorsal and ventral limb muscle at HH stage 28 (Fig. 1B).
Follistatin was also expressed in the wing muscle but did
not extend as far distally as Desmin expression (Figs. 1A
and 1G). Transverse sections additionally revealed Follista-
tin expression localised in subectodermal mesenchyme at
HH stage 28 (data not shown) and more predominantly in
muscle at HH stage 29 (Fig. 1H). Distribution of MyoD and
Pax-3 transcripts was almost identical to Desmin expres-
sion (Figs. 1A, 1C, and 1E), and transverse sections of the
zeugopod at HH stage 29 show expression of both genes in
muscle (Figs. 1D and 1F). Pax-3 transcripts, however, were
not as uniformly expressed as Desmin and MyoD. High
levels of expression rimmed the MyoD and Desmin do-
mains at the distal tip of autopod muscle. Pax-3 expression
in proximal muscle of stylopod and zeugopod were localised
to prospective individual muscle, which corresponded ap-
proximately to the sites of Follistatin expression (Figs. 1A,
1C, 1E, and 1G).
In previous work, we reported that the subdivision of
premuscle masses in Pax-3-expressing cells were situated
subectodermally, whereas MyoD-expressing cells were situ-
ated more centrally during early limb bud stages (Amthor
et al., 1998). However, concomitant to the up-regulation
of Follistatin in muscle at later limb bud stages (from
HH stage 26 onwards), MyoD-, Pax-3-, and Follistatin-
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FIG. 1. Normal expression profile of Desmin, MyoD, Pax-3, Follistatin, and BMP-2, -4, and -7 in chick wing buds. View on dorsal side of
wing buds at HH stage 28 and on transverse sections at zeugopod level at HH stages 28 and 29. (A) Desmin protein expression shows
splitting of muscle proximally whilst a compact muscle block is maintained distally (arrow). (B) Transverse section shows Desmin
expression of dorsal (arrow) and ventral muscle (arrowhead) at HH stage 28. (C) Distribution of MyoD transcripts correlates to position of
muscle (arrow, compare to A). (D) Transverse section shows MyoD expression at zeugopod level after splitting of muscle at HH stage 29
(arrows). (E) Distribution of Pax-3 transcripts correlates to position of wing muscle (compare to A) with regionalised high expression at the
zeugopod level (arrow) and at the distal front of the expression domain (arrowheads). (F) Transverse section shows Pax-3 expression at
zeugopod level after splitting of muscle at HH stage 29 (arrows). (G) Distribution of Follistatin transcripts in autopod and zeugopod (arrow)
correlates to position of muscle as shown in (A). (H) Transverse section shows predominant Follistatin expression in muscle of HH stage
29 zeugopod (arrows). (I) Expression of BMP-2, -4, and -7 after simultaneous hybridisation by using one chromophor (arrows). BMPs are
expressed at the periphery of muscle masses when compared to (A). (J) Transverse section shows BMP-2, -4, and -7 expression in some but
not all muscles (arrows), subectodermally and perichondrally at HH stage 29.
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FIG. 2. Effect of beads soaked in Follistatin on muscle development. (A) Position of Follistatin beads after implantation in wing buds at HH
stage 23. (B) Up-regulation of Pax-3 expression 1 day after Follistatin bead implantation (arrow) in the right wing compared to left. (C)
Down-regulation of MyoD expression 1 day after Follistatin bead implantation (arrow) in the right wing compared to left. (D) Up-regulation and
broadening of the MyoD expression domain (arrow) 2 days after Follistatin bead implantation in the right wing compared to left. (E) Transverse
section at zeugopod level shows down-regulation of Desmin expression predominantly in the dorsal muscle (arrow) 2 days after Follistatin bead
implantation in the right wing compared to left. Bead (green arrowhead). (F) Transverse section at zeugopod level shows Desmin expression 4 days
after Follistatin bead implantation. No significant alteration of muscle size between operated right (arrow) and unoperated left side.
FIG. 3. Effect of beads soaked in 500 g/ml BMP-7 on muscle development. (A) Position of BMP-7 beads after implantation in wing buds
at HH stage 23. (B) Lack of Pax-3 expression at site of BMP-7 bead implantation 1 day after operation (arrow) in the right wing compared
to left. Some proximal and distal expression remained (arrowheads). (C) Lack of MyoD expression at the site of BMP-7 bead implantation
1 day after operation (arrow) in the right wing compared to left. Some proximal expression remained (arrowhead). (D) MyoD expression 2
days after BMP-7 bead implantation shows smaller wing diameter, lack of dorsal zeugopod muscle, and bending of ventral muscle to the
dorsal side (arrow). (E) Implantation of BMP-7 beads resulted in a malformed wing, lack of most of the zeugopod (arrow), and some remaining
muscle at the stylopod (arrowhead) 4 days after operation as shown by Desmin expression. (F) Transverse section at level of bead implant
of the wing shown in (E) demonstrates a single bone rudiment (asterisks) and some remaining muscle (arrow). Bead (green arrowhead).
FIG. 4. Effects of simultaneous application of beads soaked in Follistatin and beads soaked in 500 g/ml BMP-7. (A) Position of Follistatin and
BMP-7 beads after implantation in HH stage 23 wing buds. (B) Up-regulation and broadening of the Pax-3 expression domain (arrow) after
Follistatin and BMP-7 bead implantation 1 day after operation in the right wing compared to left. Pax-3-positive cells scatter off distally of the
expression domain (arrowhead). (C) Lack of MyoD expression 1 day after Follistatin and BMP-7 bead implantation (arrow) in the right wing
compared to left. (D) Transverse section at zeugopod level shows up-regulation and broadening of the dorsal (arrow) and ventral MyoD expression
domain (arrowhead) 2 days after Follistatin and BMP-7 bead implantation. Bead (green arrowhead). (E) Transverse section at zeugopod level shows
lack of Desmin expression 2 days after Follistatin and BMP-7 bead implantation compared to contralateral (arrows). Bead (green arrowhead). (F)
Transverse section at zeugopod level shows gain in intensity and size of Desmin expression (arrows) 4 days after Follistatin and BMP-7 bead
implantation in the right wing compared to left. Long bone rudiments are enlarged in diameter (asterisks) compared to left.
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expressing cells appeared intermingled as demonstrated
after transverse sectioning of HH stage 29 wing zeugopods
(Figs. 1D, 1F, and 1H).
BMPs, whose activity can be modulated by Follistatin,
have been analysed at later limb bud stages by in situ
hybridisation against BMP-2, -4, and -7 transcripts simulta-
neously and visualised by using a single chromophore. At
HH stage 28, BMPs were expressed in close proximity to
limb muscle (Fig. 1I, compare to Fig. 1A), but not in limb
muscle when sections of the zeugopod were analysed (data
not shown). Interestingly, at HH stage 29, BMP expression
was found in some but not all muscle of the wing zeugopod
after transverse sectioning (Fig. 1J). For expression of indi-
vidual BMPs, refer to Amthor et al. (1998), Francis et al.
(1994), and Merino et al. (1999).
Effect of Follistatin on Pax-3 and MyoD Expression
In the next set of experiments, we explored the mecha-
nism of how Follistatin influences muscle growth. We
tested the effect of Follistatin protein on the proliferating
and differentiating myogenic cell population by analysing
the expression of Pax-3, MyoD, and Desmin. We implanted
beads soaked in Follistatin protein into wing buds at stages
prior to the onset of Follistatin expression and thereby
avoided the effects of the endogeneous protein. One to six
Follistatin beads were applied to the dorsal wing mesen-
chyme of HH stages 17–23, and distribution of Pax-3 and
MyoD transcripts and Desmin protein were examined at
different times after the operation (Fig. 2A). We found an
up-regulation of Pax-3 expression in dorsal and ventral
premuscle masses 12–34 h after operation in whole-mount
wings and on transverse sections of the prospective zeugo-
pod region compared to the unoperated left wing (38 of 44
cases; Fig. 2B). Two days after Follistatin bead implantation,
no difference was found in the intensity of Pax-3 expression
between operated and contralateral unoperated wings (5/5;
data not shown). Examination of MyoD transcripts after
Follistatin bead implantation showed a smaller domain of
expression after 14–28 h (20/25; Fig. 2C). The MyoD-
suppressing activity of Follistatin was only transient, since
2 days after bead implantation the expression domain was
broader especially in the region of stylopod muscle of the
operated whole-mount wing and after transverse sectioning
compared to contralateral (4/4; Fig. 2D). However, 4 days
after Follistatin bead implantation, no significant difference
in MyoD expression could be detected between operated
and unoperated wings (4/4; data not shown). Even though
the domain of MyoD expression expanded 2 days after
Follistatin bead implantation, Desmin expression was
down-regulated in dorsal premuscle masses after such an
operation (4/4; Fig. 2E). Again, the reduction of Desmin
expression was only transient, since 4 days after Follistatin
bead implantation no clear differences were found either in
size of muscle or in intensity of Desmin expression be-
tween manipulated and contralateral nonmanipulated
wings both on whole mounts and on transverse sections of
the zeugopod (4/4; Fig. 2F).
In summary, Follistatin stimulated Pax-3 expression and
transiently prevented the activation of MyoD and Desmin
expression. After being maintained for a prolonged period in
a Pax-3-expressing state, the myogenic cells eventually
differentiated. Thus, Follistatin acted as a proliferative
signal; however, this stimulation of muscle growth was not
strong enough to effect muscle size.
The Interaction of Follistatin and BMP-7
during Limb Muscle Development
Next, we asked whether Follistatin could modulate BMP
activity during muscle development. First, we implanted
five beads soaked in different concentrations of BMP-7
(10–500 g/ml) into the dorsal wing mesenchyme of HH
stage 22/23 embryos. The BMP-7 beads were implanted
around a control bead soaked in PBS in the centre of the
dorsal wing mesenchyme (Fig. 3A). In a second experiment,
we replaced the PBS bead by a Follistatin bead, and in a
third experiment, we additionally positioned five Follista-
tin beads between the BMP-7 beads (Fig. 4A). Sixteen hours
to 4 days after bead implantation, wings were examined for
the expression of Pax-3, MyoD, and Desmin and the pres-
ence of BMP-induced apoptosis.
Beads soaked in 500 g/ml BMP-7 induced massive levels
of apoptosis around the beads, judged by the incorporation
of Acridine Orange 16–24 h after implantation (8/8; Figs.
5A–5C). Apoptotic activity was confined predominantly to
the prospective zeugopod region. The diameter of the limb
was reduced, indicating loss of cellular material due to cell
death. However, the beads still had approximately the same
position and distance to each other compared to their
location following implantation. In situ hybridisation re-
vealed a loss in Pax-3 expression over the area where
apoptosis was observed 17–24 h after bead implantation
(10/10; Fig. 3B). Some Pax-3 expression was conserved
proximally and distally to implanted beads (Fig. 3B). Pax-3
expression of the ventral premuscle mass was not affected,
which was confirmed after transverse sectioning of the
operated right wing compared to left (data not shown). We
also found a lack of MyoD expression around the operated
region 17–24 h after bead implantation compared to con-
tralateral (7/7; Fig. 3C). Again, some of the proximal and
distal and most ventral MyoD expression was conserved at
this stage (Fig. 3C). Two days after BMP-7 bead implanta-
tion, loss of tissue, especially in the zeugopod region, was
more obvious (Fig. 3D). The diameter of the zeugopod was
greatly reduced and originally, evenly spaced beads now
were situated next to each other. Examination of MyoD and
Desmin expression showed that dorsal zeugopod and auto-
pod muscle were completely missing (8/8; Fig. 3D). Exami-
nation of sections from these limbs revealed that the
ventral musculature was present and bent towards the
dorsal side (Fig. 3D). Four days after bead implantation, the
wing was completely malformed and twisted (5/5; Fig. 3E).
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Transverse sectioning of such a wing failed to reveal a
recognisable zeugopod (Fig. 3F). Instead, a single long bone
rudiment was found, which was linked directly to the wrist
and a relatively normal autopod. It was difficult to deter-
mine whether the bone rudiment was part of the humerus
or the remnant of the radius or ulna. Examination of MyoD
and Desmin expression demonstrated the presence of some
muscle surrounding the single long bone rudiment. Auto-
pod muscle was found only on the ventral side (Figs. 3E
and 3F).
Therefore, exposure of limb mesenchyme to high concen-
tration of BMP-7 protein resulted in induction of high levels
of apoptosis. The application of BMP to the prospective
zeugopod mesenchyme resulted in a highly dysmelic limb
which lacked most of the zeugopod.
In the next set of experiments, we analysed whether
BMP-7 alone could induce the development of muscle at a
low concentration. We titrated BMP-7 to find the highest
concentration of BMP-7 that does not induce apoptosis. We
found that BMP-7 at a concentration of 25 g/ml did not
induce apoptosis (3/3). In a manner identical to our previous
work on BMP-4, we found that BMP-7 beads at this concen-
tration enhanced Pax-3 expression (3/3) during the first 24 h
after protein application (see Amthor et al., 1998). We
extended this study and determined the effects of low
concentration of BMP-7 on the long-term development of
muscle. Application of 25 g/ml BMP-7 led to the down-
regulation of MyoD expression (3/3) for up to 48 h after
protein application (Fig. 6B). In the same time period,
Desmin expression was completely inhibited in the devel-
oping limb bud (Fig. 6D). After a total of 72 h after BMP-7
application, the expression of MyoD was higher than the
control limb bud (Fig. 6F). During this time period, not only
was the expression of Desmin reinstated to its normal
pattern, but transverse sections of the zeugopod region
demonstrated that BMP-7 had induced the formation of
extra muscle (Fig. 6H).
Thus, at subapoptotic concentration, BMP-7 acts as a
proliferation factor on myogenic cells.
Implantation of one Follistatin bead encircled by five
beads soaked in 500 g/ml BMP-7 prevented induction of
apoptosis around the Follistatin bead, but apoptotic nuclei
could still be detected at the periphery of the BMP-7 beads
16 h after bead implantation (6/6; data not shown). Implan-
tation of five BMP-7 beads with an additional six Follistatin
beads completely prevented induction of apoptosis when
analysed 16–23 h after operation (6/6; Figs. 5D–5F). A few
fluorescent nuclei were detected at the anterior margin of
the operated and contralateral unoperated wing, indicating
naturally occurring apoptosis in the anterior necrosis zone.
Examination of Pax-3 17–23 h after operation showed an
up-regulation and a broadening of the expression domain
both of the dorsal and ventral premuscle masses and a
thickening of the Pax-3-expressing cell layer on transverse
sections compared to contralateral (8/8; Fig. 4B). At the
distal tip of the premuscle masses, Pax-3-positive cells
dispersed away from the main block of Pax-3-expressing
tissue and migrated into regions of limb mesenchyme
where they would not normally be localised. Examination
of MyoD expression revealed a complete lack of transcripts
in the operated wing in both the dorsal and ventral sides
16–25 h after manipulation (7/7; Fig. 4C). Two days after
operation, MyoD expression was up-regulated and the ex-
pression domains were enlarged both dorsally and ventrally,
and transverse sections revealed that the MyoD-expressing
cell layer had thickened (4/4; Fig. 4D). However, Desmin
expression was almost completely down-regulated at this
stage of development compared to the contralateral unop-
erated wing (4/4; Fig. 4E). Four days after operation, limbs
had a normal macroscopic appearance. MyoD and Desmin
expression were up-regulated in all limb muscles, and
transverse sections of the zeugopod revealed a massive gain
in muscle size and a stronger expression of Desmin in all
muscle compared to contralateral wing (5/5; Fig. 4F). Inter-
estingly, the correct muscle pattern was well preserved.
Most surprisingly, not only did the muscle increase in size
but so did the long bone rudiments (Fig. 4F).
These results show two effects of Follistatin. First, it can
completely antagonise apoptotic activity of BMP-7. Second,
the effect of Follistatin to induce Pax-3 expression is
drastically enhanced in combination with BMP-7. Both
molecules together exert strongest proliferative activity
during muscle growth.
In the next experiment, we analysed whether Follistatin
antagonises the Pax-3-inducing effect of low concentration
BMP-7. We simultaneously implanted Follistatin beads and
beads soaked in 25 g/ml BMP-7 to HH stage 21 wing buds.
We found an up-regulation of Pax-3 expression 1 day after
operation compared to the contralateral unoperated wing in
whole mounts as well as after transverse sectioning (3/3;
data not shown).
Thus, Follistatin specifically antagonises the apoptosis-
inducing activity but not the Pax-3-inducing activity of
BMP-7.
Control Experiments
In previous work, we demonstrated that implantation of
heparin acrylic beads into wing bud mesenchyme soaked in
PBS did not alter expression of Pax-3 or MyoD nor did they
interfere with the ultrastructure of the tissue (Amthor et
al., 1998). Here, we performed control experiments and
implanted six beads soaked in PBS into HH stage 22/23
wing bud mesenchyme to mimic the multiple bead im-
plants used in our experiments. Apoptosis was not induced
17–24 h after the implantation of six beads soaked in PBS
(6/6; data not shown). Fluorescent nuclei were observed
only in anterior necrosis zone in both operated and unop-
erated wings. In situ hybridisation failed to detect any
alterations in the expression of Pax-3 (4/4) or MyoD (4/4)
24 h after PBS bead implantation (data not shown). We
previously analysed the effect of BMPs applied at high
concentration on the ultrastructure of limb mesenchyme
and found no signs of unspecific necrosis, such as an
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FIG. 5. (A–C) Implantation of beads soaked in 500 g/ml BMP-7 (C) resulted in massive induction of apoptosis as shown by fluorescent
spots after Acridine Orange staining (B, arrows) 1 day after operation compared to the unoperated contralateral side (A) at which apoptotic
nuclei are found only at the anterior necrosis zone (arrowhead). (D–F) Implantation of beads soaked in Follistatin and beads soaked in 500
g/ml BMP-7 (F) prevented apoptosis at the site of bead implantation (E) Apoptotic nuclei are only found in the anterior necrosis zone
(arrow) similar to the contralateral unoperated wing (D, arrowhead).
FIG. 6. Effect of the application of low doses of BMP-7 (25 g/ml) to limb muscle development. Five beads soaked in BMP-7 were applied to
stage 20/21 limb buds and examined for myogenic markers following reincubation for 48 (stage 26) or 96 h (stage 30). (A) Stage 26 contralateral
control showing strong uniform expression of MyoD. (B) Operated side of (A) shows that MyoD was slightly down-regulated in proximal regions
(arrowheads) corresponding to the position of the BMP-7 beads. (C) Stage 26 contralateral control showing strong expression of Desmin in the
limb (arrowhead). (D) Operated side of (C) shows that, following BMP-7 implantation, Desmin levels were significantly reduced (arrowhead). (E)
Stage 30 contralateral control shows MyoD expression in individual muscles (arrowheads). (F) Stage 30 operates, side of (E) shows similar
expression profile to unoperated side with higher levels of MyoD in proximal muscle (arrowheads). (G) Transverse section of contralateral control
stage 30 limb at the zeugopod level showing Desmin expression located in discrete muscle blocks (arrowheads). (H) Transverse section of operated
side of (G) at zeugopod level showing increased levels of Desmin expression following implantation of BMP-7 (arrowheads).
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FIG. 7. (A) Expression of Noggin (arrow) 36 h after Noggin-RCAS virus injection of the right wing compared to left. (B) Transverse section
of the Noggin transfected wing which is shown in (A) demonstrates scattered expression of Noggin throughout the wing mesenchyme. (C)
Down-regulation of Pax-3 expression 36 h after Noggin transfection of the right wing compared to left. (D) Down-regulation of Pax-3
expression 62 h after Noggin transfection of the right wing compared to left. (E) Smaller expression domain of MyoD 36 h after Noggin
transfection of the right wing compared to left. (F) Smaller expression domain of MyoD shows retarded muscle development 62 h after
Noggin transfection of the right wing compared to left.
FIG. 8. Kinetic of Follistatin–BMP-7 protein interaction by using surface plasmon resonance (Biacore). Association of Follistatin–BMP-7
complexes is shown by increasing resonance units (RU) as the Follistatin flow cell was exposed to different concentrations of BMP-7 for
approximately 200 s. Dissociation of Follistatin–BMP-7 complexes is shown by decreasing RU for the different BMP-7 concentrations after
exposure of the Follistatin flow cell to buffer for approximately 800 s.
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amorphous mass of cell debris, tissue coagulation, and
swelling of cells (Amthor et al., 1998). We also examined
whether the deposition of a high concentration of protein
into limb mesenchyme could nonspecifically result in
apoptosis as a result of an alteration in the colloidosmotic
pressure. We inserted six beads soaked in Follistatin into
the dorsal wing mesenchyme of HH stage 17 embryos and
tested for induction of apoptosis 17 h after operation.
Follistatin did not induce apoptosis, and the only sign of
cell death was found in the anterior necrosis zone (2/2; data
not shown).
The Effect of Noggin on Limb Muscle Development
Our results suggested that Follistatin only partially an-
tagonises BMP signalling on limb muscle. This raised the
question of whether this feature was specific to Follistatin
or whether it was a general feature common to other
BMP-binding proteins.
We questioned the role of Noggin during limb muscle
development and infected HH stage 17 wing buds with
replication-competent retrovirus encoding the Noggin gene.
Approximately 36–48 h after infection, the limb buds had
developed to HH stage 24/25 and Noggin was expressed
throughout the wing bud mesenchyme (3/3; Figs. 7A and
7B). Infected wing buds appeared slightly shorter in proxi-
modistal axis than the noninfected contralateral wing.
Examination of Pax-3 expression in Noggin-infected wing
buds showed a drastic down-regulation of the gene 36 h
after operation (2/3; Fig. 7C). Analysis for MyoD expression
showed a proximodistal truncation of the expression do-
main concomitant to truncation of the wing (3/3; Fig. 7E).
Analysis of infected wings 62 h after Noggin infection
showed severe shortening of the wing bud together with an
anterior extension of the apical ectodermal ridge in most
cases. Pax-3 expression was either totally abolished (1/3) or
severely reduced (2/3; Fig. 7D). MyoD expression was
slightly down-regulated and the musculature was reduced
in size as the whole limb was shortened (3/3; Fig. 7F).
An alkaline-phosphatase (AP)-RCAS construct was used
as a control. Ten embryos injected with the AP virus at an
identical stage to the Noggin virus resulted in normal
expression of Pax-3 and MyoD (data not shown).
Next, we determined the consequences on muscle devel-
opment of locally expressed Noggin. We grafted RCAS cells
carrying the Noggin gene into the centre of HH stage 20–22
wing bud mesenchyme. Twenty-four hours after grafting,
Noggin expression was found in a centrally located band
along the proximodistal axis (5/5; data not shown). Wing
buds appeared shorter after ectopic Noggin expression com-
pared to contralateral nontreated wings. Molecular analysis
showed down-regulation of the Pax-3 expression 17–24 h
after grafting (10/11; data not shown). MyoD expression was
found to be normal 15 h after grafting but the expression
domain was split due to grafted cells (3/4; data not shown).
However, longer reincubation resulted in shortened wings
and concomitantly in a shortened domain of MyoD expres-
sion (5/5; data not shown).
These results demonstrate that Noggin inhibits Pax-3
expression, which leads to a reduced size of premuscle
masses as marked by MyoD expression. Thus, Noggin
impairs continuous growth of embryonic muscle and this is
in contrast to the growth-stimulation effect of Follistatin.
The Kinetic of the Follistatin–BMP Interaction
We investigated the nature of interaction between Fol-
listatin and BMP-7 in order to understand the ability of
Follistatin to potentiate the Pax-3-inducing capacity of
BMP-7. To elucidate this phenomenon, we analysed the
kinetics of Follistatin–BMP protein interaction using a
surface plasmon resonance biosensor (Biacore). The same
Follistatin and BMP-7 proteins were used as for the bead
experiments. In a first step, Follistatin was irreversible
bound with 657.3 response units onto a dextran-coated float
cell. In a second step, the same Follistatin-coated cell was
exposed to different concentrations of BMP-7 and BMP-2
proteins. The Follistatin–BMP interaction was measured in
response units from which association and dissociation
constants were calculated by using Biacore evaluation soft-
ware.
Follistatin–BMP-7 interaction was studied at 1.563,
3.125, 6.25, and 12.5 nM (Fig. 8). Experimental curves of the
kinetics were mathematically adapted by Langmuir curves,
which resulted in an average association rate of Ka  2.06
106 M1s1 and average dissociation rate of Kd  1.66 103
s1. From the association and dissociation rate constants,
the affinity (KD) of Follistatin for BMP-7 was calculated to
be 80 nM.
Follistatin–BMP-2 interaction was studied at 1.563,
3.125, 6.25, 12.5, and 25 nM (data not shown). Experimental
curves of the kinetics were mathematically adapted by
Langmuir curves which resulted in an average association
rate of Ka  1.29  106 M1s1 and average dissociation rate
of Kd  6.82  103 s1. From the association and dissocia-
tion rate constants, the affinity (KD) of Follistatin for BMP-2
was calculated to be 5.29 nM.
These results show that Follistatin and BMP-7, which
were used throughout the study, could interact directly.
The calculated affinities for Follistatin to bind BMP-7 and
BMP-2 are very similar to the affinity calculated by Iemura
et al. (1998) for Follistatin to binding to BMP-4.
DISCUSSION
The biological activity of polypeptide growth factors
is specifically regulated by various binding proteins
(Christian, 2000). Here, we present data which suggest that
the ability of BMPs to stimulate myogenic proliferation and
embryonic muscle growth is promoted by Follistatin but
inhibited by Noggin. Thus, two BMP-binding proteins
modulate the effect of BMP on muscle in opposite ways.
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In our previous work, we demonstrated that BMPs sup-
port growth and positioning of muscle in a dose-dependent
manner (Amthor et al., 1998). We showed that, at high
concentrations, BMPs induce apoptosis in muscle cells, and
we noted that, during normal chick limb development,
migrating muscle precursors avoid regions of high BMP
expression that could enable exact positioning of premuscle
masses. However, at low concentrations, BMPs maintain a
pool of Pax-3-expressing proliferating muscle precursors.
Muscle growth occurs as cells are recruited from the pre-
cursor population. Once they escape the influence of the
proliferation supporting signal, they enter a differentiated,
postmitotic muscle state signified by the onset of MyoD
expression. We showed that the ectoderm and subectoder-
mal mesenchyme express low levels of BMPs and are
adjacent to populations of cells that express Pax-3. Differ-
entiated muscle was found towards the centre of the limb
mesenchyme. Signals from the ectodermal regions main-
tain this organisation. After ectoderm removal, all Pax-3-
expressing precursors differentiate immediately, which en-
larges muscle in short term but arrests muscle growth in
long term because the pool of proliferating Pax-3-expressing
cells is depleted. Thus, proliferation signals from the ecto-
derm suffice to sustain muscle growth during early limb
bud stages when the precursors are present as a continuous
layer immediately underneath the ectoderm. However, it
would be difficult to implement such an organisation later
during development when muscle is bigger and forms
individual units at various positions.
Biological assays based on Xenopus dorsal mesoderm
formation and neuroectoderm induction have been used to
identify molecules which negatively regulate the inhibitory
actions of the BMPs in these processes. This list includes
Noggin, Follistatin, Chordin, Gremlin, Cerberus, and DAN
(Fainsod et al., 1997; Piccolo et al., 1996, 1999; Stanley et
al., 1998; Zimmerman et al., 1996). In the context of muscle
development, one molecule, Noggin, fits all the criteria of a
classical BMP antagonist. During somite development, ec-
topic expression of Noggin results in a down-regulation of
Pax-3 expression and an up-regulation of MyoD expression.
During limb development, Noggin prevents BMP-induced
apoptosis (Capdevila and Johnson, 1998; Hirsinger et al.,
1997). In this study, we have shown that overexpression of
Noggin represses Pax-3 expression, which leads to impair-
ment of muscle growth in the chick limb.
It is therefore remarkable that myogenic cells exposed to
Follistatin actually increase Pax-3 expression and tran-
siently delay differentiation. Thus, Follistatin, originally
described as a BMP antagonist during Xenopus develop-
ment, acts as a proliferation-promoting reagent during
muscle development, and therefore Follistatin acts as an
agonist of BMP signalling.
Furthermore, we showed that application of Follistatin
together with BMP-7 at a concentration which would
normally induce apoptosis completely prevents the apopto-
tic effect. Instead of loss of premuscle masses, Follistatin
together with BMP-7 stimulate Pax-3 expression and de-
layed the onset of differentiation for at least 24 h. Such an
enormous burst of precursor proliferation results in
excessive-sized muscle after myogenic cells eventually dif-
ferentiated. Thus, Follistatin acts as an agonist of BMP-7 in
its activity to promote Pax-3 expression but antagonises
BMP-7 in its activity to induce apoptosis and muscle loss.
The effect of Follistatin to partially function as an agonist
and antagonist of BMP-7 activity is reflected by the low
affinity of Follistatin to bind BMP-7 of 80 nM. This affinity
is similar for Follistatin binding to BMP-2 as well as BMP-4
(Iemura et al., 1998) but is approximately 240-fold weaker
than the affinity of Noggin to bind BMP (Zimmerman et al.,
1996). Furthermore, by studying the association and disso-
ciation kinetics of BMPs and Follistatin, we found that
Follistatin binds BMPs quite rapidly but was also able to
dissociate.
These results suggest that Follistatin binds BMPs, and in
the bound form, the activity of the BMP is neutralised.
However, the binding seems to be reversible and released
BMP regains biological activity. We propose that Follistatin
stores and presents BMPs in a subapoptotic concentration
which promotes continuous muscle growth.
Although we have demonstrated the ability of Follistatin
to bind and to lower the biological concentration of BMP-7
in an experimental scenario, we are aware that in vivo there
are members of the TGF- family other than the BMPs
which influence muscle development. Activin and Myo-
statin are expressed in developing skeletal muscle (Link and
Nishi, 1997; McPherron et al., 1997). Follistatin can bind
activin with high affinity and prevents activin signalling in
various biological systems (Hemmati-Brivanlou et al., 1994;
Michel et al., 1993; Schneyer et al., 1994). Activin can
repress muscle differentiation in culture, but the exact role
of activin and possible interaction with Follistatin during
muscle development remains to be determined (Link and
Nishi, 1997). Myostatin prevents hyperplasia and hypertro-
phy muscle, and in vitro, it inhibits muscle differentiation
(McPherron et al., 1997; Taylor et al., 2001; Thomas et al.,
2000; Zhu et al., 2000). However, Myostatin is unlikely to
be a target molecule of Follistatin because preliminary data
of protein interaction using surface plasmon resonance
failed to show binding between these molecules (unpub-
lished observations).
Our previous study and data presented in this study show
that BMPs are able to promote muscle growth (Amthor et
al., 1998). Therefore, if Follistatin would act as a BMP
antagonist, then genetic deletion of the Follistatin gene
should result in increased muscle mass. However, the
opposite is actually the case because Follistatin/ mice
present muscle defects which result in postnatal asphyxia
(Matzuk et al., 1995). Thus, the Follistatin/ phenotype
supports the mode of action suggested by this study.
We have shown that muscle in late-stage limb buds
expresses Follistatin as well as BMPs and that Pax-3-,
MyoD-, and Desmin-expressing cells appear intermingled.
The simple linear organisation of muscle seen during early
limb bud development (growth factor adjacent to precursor
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cells adjacent to differentiated cells) has clearly broken
down. We suggest that during later muscle development
Follistatin acts as a store of BMPs within the muscles
themselves and thereby maintains a pool of proliferative
active myoblasts necessary for continuous muscle growth
and secondary fibre formation. By distributing muscle
growth-regulating factors locally, individual muscles could
develop at different rates.
We have also shown that Follistatin in combination with
BMP-7 induces enlargement of long bone rudiments. These
results suggest that Follistatin may also regulate the devel-
opment of tissues other than muscle. Indeed, Follistatin/
mice are generally reduced in size and show abnormalities
in the skeletal system (Matzuk et al., 1995).
The results from this study suggest a new role for
Follistatin in which it enhances the action of BMPs by
acting as a reservoir. There are clear differences between the
biochemical properties of Follistatin and the other BMP-
interacting proteins. First, whereas Noggin and Chordin
inhibit BMPs interacting with the BMP receptors (Piccolo et
al., 1996; Zimmerman et al., 1996), Iemura et al. (1998)
have recently shown that BMPs bound to Follistatin can
still complex to its receptor. They suggest that, even though
the Follistatin—BMP complexes can bind the BMP recep-
tor, the conformation of receptor attachment is altered and
the BMP cannot induce a signalling cascade. Secondly, the
affinity for Follistatin to bind BMPs is much weaker com-
pared to Chordin and Noggin (Iemura et al., 1998; Piccolo et
al., 1996; Zimmerman et al., 1996). And lastly, recent work
by Iemura et al. (1999) has demonstrated the presence of
molecules which specifically regulate the binding of Fol-
listatin to BMPs. They have shown that Ep45, when bound
to BMP-4, prevents Follistatin interacting with BMPs, and
under these conditions, the BMP is refractory to the action
of Follistatin. Ep45, however, cannot prevent the inhibitory
action of Chordin or Noggin on BMPs. The deployment of
molecules such as Ep45 could be used to further regulate
the activity of BMPs by inhibiting the inhibitors. It will be
interesting to determine whether molecules such are Ep45
are expressed during chick limb development at stages
when Follistatin becomes localised to muscle.
In summary, we have presented data indicating that
Follistatin does not act as a classical BMP antagonist. The
low affinity of Follistatin for BMPs indicates that the
binding of these proteins is reversible. We suggest that
Follistatin expressed in muscle may locally store and
present BMPs at a defined concentration which enables
continuous muscle growth.
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